Tustin, CA - Integrium Clinical Research announced they will be attending the Redefining Early Stage Investments (RESI) Conference on April 11th, 2016 in Houston, TX. Being proud attendees of the RESI conference for many years in a row, Integrium is excited to meet with old and new connections that come together to witness some of the hottest upcoming biotech and medtech companies around the globe. Integrium representatives will be meeting with numerous health care professionals to discuss clinical synergies, capital raising, and other significant topics pertaining to biotech.
The conference not only allows attendees to be educated on the latest current events in biotech, but provides room for connections to be made in hopes of future prospects and endeavors. RESI will gather hundreds of attendees from investment firms, medtech and digital health companies, to emerging biotechs and more to the April 11th event.
As RESI has consistently delivered valuable resources, the conference will remain strong in providing long-standing relationships between early stage life science companies and investors. This years’ RESI conference is being sponsored by Johnson & Johnson Innovation JLabs, Texas Medical Center Accelerator, and Life Science Nation.
Through a trusted partnership with Proof of Concept Capital, Integrium is able to assist Micro Cap, Small Cap, and Privately held Biotechs looking to raise additional financing, by providing new clinical data to create the next bump in valuation. Integrium’s areas of therapeutic focus include Cardiovascular, Metabolic, Renal, Inflammatory, Dermatology, Wound Healing, Gene Therapy, and Orphan Diseases.
To learn more about Integrium Clinical Research, please contact:
Executive Director, Business Development
Phone: (908) 295-4578